Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Reply to Lagier et al.

Khanna S, Button JE, Lombardo MJ, Vulic M, Henn MR, Cook DN, Pomerantz RJ, Hohmann EL.

J Infect Dis. 2017 Jan 1;215(1):162-164. doi: 10.1093/infdis/jiw490. Epub 2016 Oct 20. No abstract available.

PMID:
28077592
2.

A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection.

Khanna S, Pardi DS, Kelly CR, Kraft CS, Dhere T, Henn MR, Lombardo MJ, Vulic M, Ohsumi T, Winkler J, Pindar C, McGovern BH, Pomerantz RJ, Aunins JG, Cook DN, Hohmann EL.

J Infect Dis. 2016 Jul 15;214(2):173-81. doi: 10.1093/infdis/jiv766. Epub 2016 Feb 8.

PMID:
26908752
3.

Generation of retroviral particles for the spleen necrosis virus (SNV)-based vector system and their use in transduction of various cell types.

Parveen Z, Mukhtar M, Pomerantz RJ.

Cold Spring Harb Protoc. 2010 Jun;2010(6):pdb.prot5435. doi: 10.1101/pdb.prot5435.

PMID:
20516173
4.

Combined effects of hyperglycemic conditions and HIV-1 Nef: a potential model for induced HIV neuropathogenesis.

Acheampong EA, Roschel C, Mukhtar M, Srinivasan A, Rafi M, Pomerantz RJ, Parveen Z.

Virol J. 2009 Oct 30;6:183. doi: 10.1186/1743-422X-6-183.

5.

The challenge of finding a cure for HIV infection.

Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ.

Science. 2009 Mar 6;323(5919):1304-7. doi: 10.1126/science.1165706. Review.

PMID:
19265012
6.

Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity.

Owe-Young R, Webster NL, Mukhtar M, Pomerantz RJ, Smythe G, Walker D, Armati PJ, Crowe SM, Brew BJ.

J Neurochem. 2008 May;105(4):1346-57. doi: 10.1111/j.1471-4159.2008.05241.x. Epub 2008 Jan 21.

7.

Antiviral potentials of medicinal plants.

Mukhtar M, Arshad M, Ahmad M, Pomerantz RJ, Wigdahl B, Parveen Z.

Virus Res. 2008 Feb;131(2):111-20. Epub 2007 Nov 5. Review.

PMID:
17981353
8.

Pentoxifylline suppresses transduction by HIV-1-based vectors.

Smith JA, Nunnari G, Preuss M, Pomerantz RJ, Daniel R.

Intervirology. 2007;50(5):377-86. Epub 2007 Oct 15.

PMID:
17938572
9.

Hide-and-seek: the challenge of viral persistence in HIV-1 infection.

Geeraert L, Kraus G, Pomerantz RJ.

Annu Rev Med. 2008;59:487-501. Review.

PMID:
17845138
10.

Effects of highly active antiretroviral therapy on HIV-1-associated oral complications.

Parveen Z, Acheampong E, Pomerantz RJ, Jacobson JM, Wigdahl B, Mukhtar M.

Curr HIV Res. 2007 May;5(3):281-92. Review.

PMID:
17504170
11.

Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.

McKenna PM, Koser ML, Carlson KR, Montefiori DC, Letvin NL, Papaneri AB, Pomerantz RJ, Dietzschold B, Silvera P, McGettigan JP, Schnell MJ.

J Infect Dis. 2007 Apr 1;195(7):980-8. Epub 2007 Feb 20.

PMID:
17330788
12.

HIV-1 Vpr potently induces programmed cell death in the CNS in vivo.

Cheng X, Mukhtar M, Acheampong EA, Srinivasan A, Rafi M, Pomerantz RJ, Parveen Z.

DNA Cell Biol. 2007 Feb;26(2):116-31. Erratum in: DNA Cell Biol. 2007 Mar;26(3):192. Cheng, Xiandong [corrected to Cheng, Xiaodong].

PMID:
17328670
13.

Cholesterol-depleting statin drugs protect postmitotically differentiated human neurons against ethanol- and human immunodeficiency virus type 1-induced oxidative stress in vitro.

Acheampong E, Parveen Z, Mengistu A, Ngoubilly N, Wigdahl B, Lossinsky AS, Pomerantz RJ, Mukhtar M.

J Virol. 2007 Feb;81(3):1492-501. Epub 2006 Nov 15.

14.

Mutation of the Rev-binding loop in the human immunodeficiency virus 1 leader causes a replication defect characterized by altered RNA trafficking and packaging.

Greatorex JS, Palmer EA, Pomerantz RJ, Dangerfield JA, Lever AM.

J Gen Virol. 2006 Oct;87(Pt 10):3039-44.

PMID:
16963763
15.

Inhibition of endogenous reverse transcription of human and nonhuman primate lentiviruses: potential for development of lentivirucides.

Argyris EG, Dornadula G, Nunnari G, Acheampong E, Zhang C, Mehlman K, Pomerantz RJ, Zhang H.

Virology. 2006 Sep 30;353(2):482-90. Epub 2006 Jul 21.

16.

Rabies virus glycoprotein as a carrier for anthrax protective antigen.

Smith ME, Koser M, Xiao S, Siler C, McGettigan JP, Calkins C, Pomerantz RJ, Dietzschold B, Schnell MJ.

Virology. 2006 Sep 30;353(2):344-56. Epub 2006 Jul 3.

17.

siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects.

Dave RS, McGettigan JP, Qureshi T, Schnell MJ, Nunnari G, Pomerantz RJ.

Virology. 2006 May 10;348(2):489-97. Epub 2006 Feb 9.

18.

Anti-HIV-1 microbicides -- 'chemical condoms' designed to limit the scourge of the HIV-1 pandemic.

Scholand SJ, DeSimone JA, Pomerantz RJ.

Curr Pharm Des. 2005;11(29):3747-56. Review.

PMID:
16305509
19.

IL-7 as a potential therapy for HIV-1-infected individuals.

Nunnari G, Pomerantz RJ.

Expert Opin Biol Ther. 2005 Nov;5(11):1421-6. Review.

PMID:
16255646
20.

T-Cells and excitotoxicity: HIV-1 and other neurodegenerative disorders.

Mukhtar M, Acheampong E, Parveen Z, Pomerantz RJ.

Neuromolecular Med. 2005;7(3):265-73. Review.

PMID:
16247186
21.

Seminal reservoirs during an HIV type 1 eradication trial.

Nunnari G, Leto D, Sullivan J, Xu Y, Mehlman KE, Kulkosky J, Pomerantz RJ.

AIDS Res Hum Retroviruses. 2005 Sep;21(9):768-75.

PMID:
16218800
22.

Exogenous IL-7 induces Fas-mediated human neuronal apoptosis: potential effects during human immunodeficiency virus type 1 infection.

Nunnari G, Xu Y, Acheampong EA, Fang J, Daniel R, Zhang C, Zhang H, Mukhtar M, Pomerantz RJ.

J Neurovirol. 2005 Aug;11(4):319-28.

PMID:
16162475
23.

HIV type 1 cervicovaginal reservoirs in the era of HAART.

Nunnari G, Sullivan J, Xu Y, Nyirjesy P, Kulkosky J, Cavert W, Frank I, Pomerantz RJ.

AIDS Res Hum Retroviruses. 2005 Aug;21(8):714-8.

PMID:
16131311
24.

Attenuation of HIV-1 infection by other microbial agents.

Kannangara S, DeSimone JA, Pomerantz RJ.

J Infect Dis. 2005 Sep 15;192(6):1003-9. Epub 2005 Aug 12. Review.

PMID:
16107952
25.

Retroviruses and opportunistic infections--eighth annual conference.

Mukhtar M, Pomerantz RJ.

IDrugs. 2001 May;4(5):515-7.

PMID:
16012887
26.

Antiretroviral therapy in the developing world.

Chulamokha L, DeSimone JA, Pomerantz RJ.

J Neurovirol. 2005;11 Suppl 1:76-80. Review. No abstract available.

PMID:
15960241
27.

AIDS Vaccine 2001. Advances in AIDS research.

Mukhtar M, Parveen Z, Pomerantz RJ.

IDrugs. 2001 Oct;4(10):1144-6. No abstract available.

PMID:
15957080
28.

Molecular interactions of human immunodeficiency virus type 1 with primary human oral keratinocytes.

Acheampong EA, Parveen Z, Muthoga LW, Wasmuth-Peroud V, Kalayeh M, Bashir A, Diecidue R, Mukhtar M, Pomerantz RJ.

J Virol. 2005 Jul;79(13):8440-53.

29.

Current status of gene therapy strategies to treat HIV/AIDS.

Strayer DS, Akkina R, Bunnell BA, Dropulic B, Planelles V, Pomerantz RJ, Rossi JJ, Zaia JA.

Mol Ther. 2005 Jun;11(6):823-42. Review.

30.

The RNA helicase DDX1 is involved in restricted HIV-1 Rev function in human astrocytes.

Fang J, Acheampong E, Dave R, Wang F, Mukhtar M, Pomerantz RJ.

Virology. 2005 Jun 5;336(2):299-307.

31.

ATM: HIV-1's Achilles heel?

Daniel R, Pomerantz RJ.

Nat Cell Biol. 2005 May;7(5):452-3. No abstract available.

PMID:
15867928
33.

Inhibition of HIV-1 replication by caffeine and caffeine-related methylxanthines.

Nunnari G, Argyris E, Fang J, Mehlman KE, Pomerantz RJ, Daniel R.

Virology. 2005 May 10;335(2):177-84.

34.
35.

Ethanol potentiates HIV-1 gp120-induced apoptosis in human neurons via both the death receptor and NMDA receptor pathways.

Chen W, Tang Z, Fortina P, Patel P, Addya S, Surrey S, Acheampong EA, Mukhtar M, Pomerantz RJ.

Virology. 2005 Mar 30;334(1):59-73.

36.

Caffeine inhibits human immunodeficiency virus type 1 transduction of nondividing cells.

Daniel R, Marusich E, Argyris E, Zhao RY, Skalka AM, Pomerantz RJ.

J Virol. 2005 Feb;79(4):2058-65.

37.

Spleen necrosis virus-based vector delivery of anti-HIV-1 genes potently protects human hematopoietic cells from HIV-1 infection.

Marusich EI, Parveen Z, Strayer D, Mukhtar M, Dornburg RC, Pomerantz RJ.

Virology. 2005 Feb 5;332(1):258-71.

38.

IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.

Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, Acheampong EA, Fisher J, Sierra M, Thomson MM, Najera R, Frank I, Kulkosky J, Pomerantz RJ, Nunnari G.

J Clin Invest. 2005 Jan;115(1):128-37.

39.

RNA interference:a potential novel therapeutic combating HIV-1 in the central nervous system.

Pomerantz RJ.

Arch Immunol Ther Exp (Warsz). 2004 Nov-Dec;52(6):401-9. Review.

PMID:
15577741
40.

The perlecan heparan sulfate proteoglycan mediates cellular uptake of HIV-1 Tat through a pathway responsible for biological activity.

Argyris EG, Kulkosky J, Meyer ME, Xu Y, Mukhtar M, Pomerantz RJ, Williams KJ.

Virology. 2004 Dec 20;330(2):481-6.

41.

A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev.

Fang J, Kubota S, Yang B, Zhou N, Zhang H, Godbout R, Pomerantz RJ.

Virology. 2004 Dec 20;330(2):471-80.

43.

Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque.

McKenna PM, Aye PP, Dietzschold B, Montefiori DC, Martin LN, Marx PA, Pomerantz RJ, Lackner A, Schnell MJ.

J Virol. 2004 Dec;78(24):13455-9.

44.

Ludwik Hirszfeld Memorial Lecture: HIV-1 reservoirs: major molecular obstacles to viral eradication.

Pomerantz RJ.

Arch Immunol Ther Exp (Warsz). 2004 Sep-Oct;52(5):297-306. Review.

PMID:
15507870
45.

Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4.

Zhou N, Fang J, Mukhtar M, Acheampong E, Pomerantz RJ.

Gene Ther. 2004 Dec;11(23):1703-12.

PMID:
15306840
46.

Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5.

Cordelier P, Kulkowsky JW, Ko C, Matskevitch AA, McKee HJ, Rossi JJ, Bouhamdan M, Pomerantz RJ, Kari G, Strayer DS.

Gene Ther. 2004 Nov;11(22):1627-37.

PMID:
15295615
47.

Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents.

Kulkosky J, Sullivan J, Xu Y, Souder E, Hamer DH, Pomerantz RJ.

AIDS Res Hum Retroviruses. 2004 May;20(5):497-505.

PMID:
15186524
49.

Effects of HIV-1 Vpr on neuroinvasion and neuropathogenesis.

Pomerantz RJ.

DNA Cell Biol. 2004 Apr;23(4):227-38. Review.

PMID:
15142380
50.

HIV-1 Vif versus APOBEC3G: newly appreciated warriors in the ancient battle between virus and host.

Argyris EG, Pomerantz RJ.

Trends Microbiol. 2004 Apr;12(4):145-8. No abstract available.

PMID:
15116720

Supplemental Content

Loading ...
Support Center